From Financialpost · · 1m 10s
Satellos Gets Patent for Muscle Regeneration Drug
Satellos wins U.S. patent for forazapadin, a drug targeting muscle regeneration in degenerative diseases.
In brief
Satellos wins U.S. patent for forazapadin, a drug targeting muscle regeneration in degenerative diseases. Satellos Bioscience received U.S. patent No. 12,747,245 for forazapadin, a drug candidate targeting muscle regeneration in degenerative diseases. Originally reported by Financialpost.
Satellos Receives U.S. Patent
Satellos Bioscience Inc. received U.S. Patent No. 12,747,245 for forazapadin, a drug candidate targeting muscle regeneration in degenerative diseases.
Patent Covers Muscle Regeneration Platform
The patent includes composition of matter claims for forazapadin and a broader class of AAK1 inhibitors within Satellos' muscle regeneration platform.
Patent Protection Through 2044
The composition of matter patent provides intellectual property protection through September 6, 2044, with potential extension after U.S. marketing approval.
CEO Highlights Patent Benefits
Frank Gleeson, Satellos' CEO, stated the patent supports long-term development and commercialization for forazapadin in degenerative muscle diseases.
Forazapadin Targets Muscle Regeneration
Forazapadin inhibits AAK1, a protein that helps restore muscle regeneration biology disrupted in degenerative conditions.
Next Steps for Forazapadin
Satellos plans to list the patent in the FDA's Orange Book after potential U.S. marketing approval for forazapadin.
The one thing
Satellos Bioscience received U.S. patent No. 12,747,245 for forazapadin, a drug candidate targeting muscle regeneration in degenerative diseases.
